×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PSTV – plus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PSTV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
07:38 am
pstv
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases [Yahoo! Finance]
Low
Report
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases [Yahoo! Finance]
11/22
07:30 am
pstv
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
Low
Report
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
11/21
07:30 am
pstv
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Neutral
Report
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
11/16
02:46 pm
pstv
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/15
08:03 am
pstv
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/15
02:34 am
pstv
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
Medium
Report
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
11/14
04:27 pm
pstv
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
04:15 pm
pstv
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Date
Time
Symbol
Headline
Impact
11/14
04:14 pm
pstv
Form 424B3 PLUS THERAPEUTICS, INC.
Medium
Report
Form 424B3 PLUS THERAPEUTICS, INC.
11/14
04:13 pm
pstv
Form 8-K PLUS THERAPEUTICS, INC. For: Nov 14
Medium
Report
Form 8-K PLUS THERAPEUTICS, INC. For: Nov 14
11/14
04:05 pm
pstv
Form 10-Q PLUS THERAPEUTICS, INC. For: Sep 30
Medium
Report
Form 10-Q PLUS THERAPEUTICS, INC. For: Sep 30
11/1
08:31 am
pstv
Form 424B3 PLUS THERAPEUTICS, INC.
Low
Report
Form 424B3 PLUS THERAPEUTICS, INC.
11/1
08:26 am
pstv
Form 8-K PLUS THERAPEUTICS, INC. For: Oct 30
Medium
Report
Form 8-K PLUS THERAPEUTICS, INC. For: Oct 30
10/4
04:12 pm
pstv
Form S-3 PLUS THERAPEUTICS, INC.
Medium
Report
Form S-3 PLUS THERAPEUTICS, INC.
9/17
07:00 am
pstv
Form 4 PLUS THERAPEUTICS, INC. For: Sep 13 Filed by: Hawkins Richard J
Medium
Report
Form 4 PLUS THERAPEUTICS, INC. For: Sep 13 Filed by: Hawkins Richard J
9/16
07:00 am
pstv
Form 4 PLUS THERAPEUTICS, INC. For: Sep 12 Filed by: Hawkins Richard J
Low
Report
Form 4 PLUS THERAPEUTICS, INC. For: Sep 12 Filed by: Hawkins Richard J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/15
Q2/2019 6/30/2019 EPS -5.120 ZacksConsensus N/A ActVsEst N/A - N/A
272.2%
3/30 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 29 57.6%
8/26 Form SC 13G PLUS THERAPEUTICS, INC. Filed by: Sassicaia Capital Advisers LLC 44.6%
11/14 Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results 17.8%
10/15 Form 8-K PLUS THERAPEUTICS, INC. For: Oct 09 10.0%
4/6 Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic 9.0%
12/9 Plus Therapeutics to Present at Biotech Showcase 2020 7.4%
9/26 Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering 6.1%
1/6 Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 5.0%
11/4 Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 4.4%
3/30 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 29 57.6%
8/26 Form SC 13G PLUS THERAPEUTICS, INC. Filed by: Sassicaia Capital Advisers LLC 44.6%
11/14 Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results 17.8%
10/15 Form 8-K PLUS THERAPEUTICS, INC. For: Oct 09 10.0%
4/6 Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic 9.0%
12/9 Plus Therapeutics to Present at Biotech Showcase 2020 7.4%
9/26 Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering 6.1%
1/6 Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 5.0%
11/4 Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 4.4%
TOP News Decliners
3/12
Form 8-K PLUS THERAPEUTICS, INC. For: Mar 09
-23.6%
8/2 Form 8-K CYTORI THERAPEUTICS, For: Aug 01 -21.6%
3/30 Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 -20.0%
8/14 Form NT 10-Q PLUS THERAPEUTICS, INC. For: Jun 30 -19.7%
8/21 Plus Therapeutics: Prepare For The Imminent Dilution [Seeking Alpha] -18.5%
7/29 Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split -15.0%
9/16 Form S-1/A PLUS THERAPEUTICS, INC. -14.5%
4/1 Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development -13.3%
9/24 Form 424B4 PLUS THERAPEUTICS, INC. -13.2%
8/9 Form 8-K PLUS THERAPEUTICS, INC. For: Aug 09 -12.5%
8/2 Form 8-K CYTORI THERAPEUTICS, For: Aug 01 -21.6%
3/30 Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 -20.0%
8/14 Form NT 10-Q PLUS THERAPEUTICS, INC. For: Jun 30 -19.7%
8/21 Plus Therapeutics: Prepare For The Imminent Dilution [Seeking Alpha] -18.5%
7/29 Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split -15.0%
9/16 Form S-1/A PLUS THERAPEUTICS, INC. -14.5%
4/1 Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development -13.3%
9/24 Form 424B4 PLUS THERAPEUTICS, INC. -13.2%
8/9 Form 8-K PLUS THERAPEUTICS, INC. For: Aug 09 -12.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: